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Abstract 
Background: Sulfadoxine–pyrimethamine (SP) is recommended for prophylactic treatment of malaria in pregnancy 
while artemisinin combination therapy is the recommended first-line anti-malarial treatment. Selection of SP resist-
ance is ongoing since SP is readily available in health facilities and in private drug shops in sub-Saharan Africa. This 
study reports on the prevalence and distribution of Pfdhps mutations A540E and A581G in Tanzania. When found 
together, these mutations confer high-level SP resistance (sometimes referred to as ‘super-resistance’), which is associ-
ated with loss in protective efficacy of SP-IPTp.
Methods: DNA samples were extracted from malaria-positive blood samples on filter paper, used malaria rapid diag-
nostic test strips and whole blood collected from eight sites in seven administrative regions of Tanzania. PCR–RFLP 
and SSOP-ELISA techniques were used to genotype the A540E and A581G Pfdhps. Data were analysed using SPSS 
version 18 while Chi square and/or Fischer Exact tests were used to compare prevalence between regions.
Results: A high inter-regional variation of Pfdhps-540E was observed (χ2 = 76.8, p < 0.001). High inter-regional varia-
tion of 581G was observed (FE = 85.3, p < 0.001). Both Tanga and Kagera were found to have the highest levels of SP 
resistance. A high prevalence of Pfdhps-581G was observed in Tanga (56.6 %) in northeastern Tanzania and in Kagera 
(20.4 %) in northwestern Tanzania and the 540–581 EG haplotype was found at 54.5 and 19.4 %, respectively. Pfdhps-
581G was not detected in Pwani and Lindi regions located south of Tanga region.
Conclusions: Selection of SP super-resistant Pfdhps A581G is highest in northern Tanzania. Variation in distribution 
of SP resistance is observed across the country: northeastern Tanga region and northwestern Kagera region have 
highest prevalence of SP super-resistance markers, while in Pwani and Lindi in the southeast the prevalence of super-
resistance was zero. More studies should be conducted to understand the factors underlying the remarkable hetero-
geneity in SP resistance in the country.
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Background
Emergence and spread of Plasmodium falciparum resist-
ance to chloroquine (CQ) and sulfadoxine-pyrimethamine 
(SP) forced the adoption of artemisinin-based combina-
tion therapy (ACT) as first-line anti-malarial drugs in 
most sub-Saharan African countries (SSA) by 2007 [1]. 
Since the introduction of ACT, SP has remained the com-
binational drug for ACT (SP-artesunate) used in a few 
SSA countries, or as a prophylactic drug in intermittent 
preventive treatment of malaria during pregnancy (IPTp) 
where three or more treatment doses of SP are adminis-
tered on a monthly basis after the first trimester. SP as a 
prophylaxis is also used in infancy (IPTi) and as a seasonal 
malaria chemoprevention (SMC) in children [2–4]. SMC 
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in particular, where SP is combined with amodiaquine, is 
currently being implemented in West African countries 
(Chad, The Gambia, Niger, Mali, Senegal, Guinea) [5], and 
it has been shown to be cost effective in reducing child-
hood morbidity and mortality due to malaria [6].
SP acts by inhibiting the folic acid synthesis in the 
malaria parasite; sulfadoxine and pyrimethamine inhibit 
the Plasmodium falciparum enzymes dihydropter-
oate synthetase (DHPS) and dihydrofolate reductase 
(DHFR), respectively [7, 8]. Resistance to sulfadoxine and 
pyrimethamine is caused by mutations in the P. falcipa-
rum dhps and dhfr genes, respectively. Pfdhfr single-point 
mutations causing amino acid changes in N51I, C59R and 
S108 N are the most common mutations associated with 
pyrimethamine resistance in SSA [9, 10] and the combi-
nation of these forming the triple Pfdhfr IRN mutation is 
highly prevalent in SSA [11, 12]. Regarding sulfadoxine 
resistance, Pfdhps mutations S436A/C/F, A437G, K540E, 
A581G, and A613S/T have been observed globally [13, 
14] and S436A/C/F, A437G and G540E are commonly 
observed in SSA [11]. The combination of the Pfdhfr triple 
and the Pfdhps double (A437G, K540E) mutations collec-
tively form the quintuple mutations [7, 15] which confers 
high-level SP resistance and is a significant predictor of 
SP P. falciparum treatment failure [16–18]. The evolution 
of the Pfdhps mutations normally occurs after the Pfdhfr 
triple mutations and thus the presence of Pfdhps double 
mutations indicates presence of quintuple mutations.
In SSA, the highest prevalence of SP resistance markers 
has been documented in East Africa where the quintu-
ple mutation has been shown to approach fixation [12]. 
Evidence shows that the quintuple mutation emerged 
in the 1990s and in Tanzania as high as over 60  % was 
detected in 1998 [19], while a recent survey documented 
more than 95  % quintuple mutation, in 2011 [20]. In 
2010, the World Health Organization (WHO), through 
its malaria advisory committee made a recommendation 
that SP-IPTi should be implemented only in areas where 
prevalence of the quintuple mutation, as represented by 
the Pfdhps 540E, is less than 50  % [21]. Given the high 
prevalence of the 540E in East Africa, this policy has led 
to the restricted recommendation of SP-IPTi to West 
Africa where the 540E mutation (and hence the quintuple 
mutation) is low or absent [11]; currently, SP-IPTi is only 
implemented in Chad [5].
In areas where the quintuple mutation is high, IPTp 
with SP does not prevent placental malaria but may con-
tinue to protect against severe pregnancy outcomes [22–
25]. WHO has continued to recommend use of at least 
three SP-IPTp doses even in such areas where the quintu-
ple mutations are high [26].
The emergence of an additional Pfdhps mutation that 
is 581G in areas where the quintuple mutant is well 
established has been documented in two major foci in East 
Africa [12]. Furthermore, in Tanzania in particular, the 
prevalence of the 581G has reached 55 % in the northeast 
[27]. Growing evidence from studies performed mainly in 
Tanzania indicates that presence of the Pfdhps 581G (sex-
tuple mutant parasites), is associated with reduced SP-
IPTp efficacy by: (1) a reduction in the protection period 
of SP-IPTp from 4 to 2 weeks [23]; (2) increased parasitae-
mia [23, 28] and recently, from a study in Malawi [29], also 
increased placental parasitaemia [28]; (3) increased risk of 
severe malaria in offspring [30]; and, (4) low birth weight 
in new-borns from mothers undergoing SP-IPTp in Tan-
zania [31]. Thus, the emergence of sextuple mutants seems 
to have a direct impact on the efficacy of the IPTp using SP. 
The existing information on the 581G distribution in Tan-
zania is scarce, mainly confined to the region of Tanga, and 
may not be evenly distributed across the country. A recent 
systematic review and meta-analysis of the influence of the 
Pfdhps 581G mutation on SP-IPTp has shown that when 
the prevalence of 581G is  >10  %, IPTp with SP does not 
protect against low birth weight [32]. For a proper, evi-
dence-based implementation of IPTp programme and an 
understanding of regions where the strategy may be com-
promised, a countrywide monitoring of the mutations 
is important. This study reports on the status of Pfdhps 
K540E and A581G in Tanzania.
Methods
Filter paper blood spot, whole blood and used malaria 
rapid diagnostic test strips collected in previous studies 
between June 2010 and August 2011 in seven regions of 
mainland Tanzania were used for this study, as previously 
described [33]. The study sites included Mwanza (Mis-
ungwi district) and Kagera (Muleba district) around Lake 
Victoria in the northwestern zone, Tanga (Muheza and 
Bondo) in the northeastern zone, Mtwara (Tandahimba 
and Mtwara-Urban), Coastal Region (Kibiti-Rufiji) and 
Lindi Region (Nachingwea) in the southeastern zone and 
Mbeya (Kyela and Rungwe districts) in the southwestern 
zone. The DNA samples were extracted using Chelex-100 
method [34]. Genotyping for Pfdhps K540E and A581G 
was performed using polymerase chain reaction-restric-
tion fragment length polymorphisms (PCR-RFLP) and 
polymerase chain reaction-single strand oligonucleotide 
probes-enzyme linked immunosorbent assay (PCR-SSOP-
ELISA) methods described by others [35–37]. All PCR rea-
gents and restriction endonucleases were purchased from 
New England Biolabs (Ipswich, MA, USA). Primers were 
purchased from Biolegio (Nijmegen, The Netherlands). 
Prevalence was calculated for each genotype, excluding 
mixed infections in both individual genotype prevalence 
and in 540-581 haplotype analysis. Only a few mixed 
infections were observed in A581G (Table 1). Maps were 
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constructed using ArcGIS version 10.2. The study received 
ethical approval from the Kilimanjaro Christian Medical 
University College Research Ethics Review Committee.
Results
Pfdhps K540E and A581G distribution
A total of 1024 samples were available for the study from 
eight sites in seven regions; 928 and 854 were successfully 
genotyped for Pfdhps K540E and A581G, respectively. 
Genotypes are summarized in Table  1. The prevalence 
of the 540E mutation was generally high in all regions 
with the highest observed in Mbeya (98.0  %) and the 
lowest in Mtwara (63.9  %). Mtwara, Lindi and Pwani 
regions had significantly lower prevalence of 540E (aver-
age 71.3 %) compared to the rest of the country (average 
92.4  %) (χ2  =  76.8, p  <  0.001). For the 581G mutation, 
Muheza and Bondo sites in Tanga region had the high-
est prevalence at 51.1 and 56.6 %, respectively, followed 
by Kagera region (Muleba) where 20.4  % was recorded. 
Contrarily, the 581G mutation was absent in Pwani and 
Lindi regions and, again by comparing the southeast 
Mtwara, Lindi and Pwani regions against the rest of the 
country, only 1.5  % of the 581G was recorded in these 
three regions compared to 22.6 % in the rest (FE = 85.3, 
p < 0.001) (Table 1; Fig. 1).
Pfdhps haplotypes
Construction of Pfdhps K540E-A581G haplotypes was 
performed and is shown in Table 1. The most prevalent 
haplotype was the EA ranging from 35.5 to 92.1 %. This 
is due to the high prevalence of the 540E as opposed to 
the 581G. The double mutant EG haplotype was most 
prevalent in Tanga, both in Muheza (51.1 %) and Bondo 
(54.5 %); it was observed at 3.6 % in Mtwara and 19.4 % in 
Kagera, while being absent in Pwani and Lindi.
Discussion
Historically, pyrimethamine has been in use in Tanga 
region since the 1950s [38]. In 1954 resistance to a weekly 
prophylactic dose of pyrimethamine was reported in 
Tanga and this was the first resistance report in Tan-
zania and in Africa [39]. SP continued both as the sec-
ond-line treatment drug [chloroquine (CQ) was the 
first-line drug] and for malaria prophylaxis until 2001, 
when it was declared the first-line drug due to high lev-
els of CQ resistance [40]. However, since resistance to SP 
had already emerged, at least in some parts of the coun-
try, SP policy in 2001 was considered a temporary solu-
tion [41] and was replaced by ACT by 2006 [42].
In the East African region, the prevalence of molecu-
lar markers of SP resistance has been increasing since 
the emergence of the first resistance-conferring muta-
tions in the 1950s. During the past decade, many of these 
mutations in Pfdhfr and Pfdhps have approached fixation 
levels, while newer mutations are still increasing [20, 27, 
43, 44]. Given the importance of preventing malaria in 
pregnancy, the growing evidence of declining effectiveness 
of the IPTp strategy in areas of high prevalence of quintu-
ple and sextuple Pfdhfr/Pfdhps haplotypes and the lack of 
an alternative to SP for use in IPTp, then the monitoring of 
SP resistance is crucial [45]. This is the first multi-site study 
in Tanzania to report on countrywide prevalence of these 
markers of SP resistance of immediate importance. The 
Pfdhps A581G mutation was first reported at low preva-
lence of 1.6 and 1.2 % in Mlimba (Morogoro) and Matema 
(Mbeya), respectively, in 2005 [46]. Surveys done in Tanga 
(Hale) in 2006 and 2007 found the mutation at prevalence 
of up to 54 % [27, 47]. In this study, Tanga region repre-
sents the highest prevalence of Pfdhps 581G followed 
by Kagera region. Highest levels of molecular markers of 
resistance (or tolerance) to other anti-malarial drugs, such 
as CQ, have also been recorded in Tanga when compared 
to other regions in Tanzania regarding mutations in Pfcrt 
(reviewed in [33]) and artemether-lumefantrine regarding 
the Pfmdr1 marker [48]. Furthermore, occurrence of the 
South Asian CQ-resistant Pfcrt haplotype SVMNT was 
also reported in Tanga for the first time [49].
Local drug pressure is mainly related to local malaria 
endemicity, which meaning that resistance levels may 
vary between different regions in Tanzania, due to their 
differences in malaria endemicity. The whole of Tanza-
nia is endemic to malaria, but the Indian Ocean coastal 
strip (Tanga, Coastal, Dar es Salaam, Lindi, Mtwara) and 
the Lake Victoria shores (Mwanza, Kagera) have gener-
ally higher malaria endemicity compared to the rest of the 
country. The high malaria endemicity in, especially, Tanga 
and Kagera may therefore partly explain the observed 
high resistance to SP in these regions due to increased 
drug pressure relative to other regions. However, the dif-
ferences in levels of resistance markers between these 
regions compared to the Coastal region, which also rep-
resents high malaria endemicity, leads to speculation that 
other local factors are contributing to local expansion of 
the 581G mutant parasites. Such factors may be related to 
local movement of the population and the in- and out-flow 
of people carrying parasites from one area to another. For 
instance, according to a study by Pindolia et  al. [50], the 
Dodoma region is a major source of both human move-
ment and malaria movement. Pindolia and colleagues have 
shown that while the majority of both human and malaria 
movement is directed towards the central and the western 
parts of the country, which do not represent major sources 
of super resistance (mainly Mbeya and Mwanza), the 
majority of the malaria movement was directed towards 
Mwanza (where there is some degree of resistance). This 
implies that the malaria movement does not correlate 
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positively with resistance. Tanga, however, which repre-
sents the highest level of SP resistance was found to repre-
sent only internal movement and no major in- or out-flow 
or neither people nor malaria, indicating that perhaps this 
setting is more isolated and prone to resistance emergence 
and accumulation, perhaps due to a lack of in-flow of new 
and diverse parasite genotypes.
Furthermore, the southern parts of the Tanzania have 
a lower level of SP resistance, whereas the trends shown 
in the present study point to the northeastern and north-
western parts bordering Kenya and Uganda, respec-
tively, having relatively higher levels of SP resistance. It 
is possible that cross-border spread of resistance con-
tributes to these observations. For instance, in western 
Kenya, Pfdhps 540E and 581G have been reported to 
have increased, respectively, from 33.1 and 0  % in 1996 
to 99.2 and 5.3 % in 2009 [43]. Related trends have also 
been reported in the same area in Kenya [51] although 
the reported prevalence of 581G is much lower than in 
Tanga and Kagera regions. In Uganda, a study performed 
in central Uganda reported Pfdhps 581G at 3.3 %, while 
another in western Uganda reported 36 % [28, 52].
Considering the combined Pfdhps K540E-A581G hap-
lotypes, the EG haplotype (540E–581G) was observed 
at highest prevalence (>50  %) in Tanga region (both 
in Muheza and Bondo sites) and in Kagera (>20  % in 
Muleba). This haplotype is common in South America and 
Cambodia [53] thus it unclear whether this has indepen-
dently evolved in Tanzania or other factors such as impor-
tation account for this. The EA highest in Mbeya and 
Mwanza regions (>90 %) was considered an East African 
haplotype, while the rarely observed wild-type KA is com-
mon in West Africa. A rare KG haplotype in was observed 
in Tanga. The KG is thought to evolve from the EG hap-
lotype and is common in Cambodia and Venezuela [53]. 
The overall distribution of Pfdhps mutation and especially 
the EG haplotype indicates that P. falciparum sensitivity to 
SP vary largely across the country, with implication for SP-
IPTp implementation. Despite the large sample set from 
across Tanzania used in this study, it is not clear if a greater 
variability can be found if further sampling is performed. 
Furthermore, intra-regional variability in resistance has 
been observed, for instance, for the case of Bondo and 
Muheza within Tanga region. Further preliminary map-
ping of the Pfdhps K540E-A581G haplotypes using 2014 
samples from Songea in Ruvuma region, which is placed 
somewhat between Mtwara and Mbeya, observed a preva-
lence of the EG haplotype of 2 % (Fig. 1), which does not 
differ much from the 5 % in neighbouring Mtwara region. 
A similar observation was made for Mwanza.
Fig. 1 Regional sites and distribution of Pfdhps polymorphisms in Tanzania. a Pfdhps K540E and b Pfdhps A581G. Mutants are shown in red and 
wild types in green. Mixed genotypes are shown in light blue. All samples were collected in 2010/2011 except data shown in purple. Shown in purple 
is preliminary data for samples collected in 2014 for Mwanza and Ruvuma regions where similarity in Pfdhps 540E and 581G prevalence between 
Ruvuma and neighbouring Mtwara region is observed
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Sporadic evidence shows that although ACT is the 
current first-line anti-malarial for treatment of uncom-
plicated malaria, the lack of proper healthcare services, 
especially in rural communities in Tanzania, as well as 
the availability of other anti-malarials in drug shops, 
encourages self-medication with non-standard regimens, 
including SP [54, 55]. It is important for national malaria 
control programmes and Ministries of Health to limit 
the availability of drugs such as SP to IPTp and/or IPTi 
programmes only. Furthermore, consideration for differ-
entiated regional implementation of SP-IPTp based on 
differences in resistance levels may be important prior 
to availability of alternatives to SP. Sustained monitoring 
of molecular markers of SP resistance, especially super-
resistance markers, should be continued with country-
wide coverage in order to enable time-point specific 
assessment.
Conclusions
Selection of SP resistance in Tanzania is high with vari-
able distribution of Pfdhps A581G SP super-resistance 
marker across the country. The northeastern Tanga 
region and the northwest Mwanza and Kagera regions 
have high prevalence of SP super resistance that may 
spread to other regions of the country. This variable dis-
tribution of SP super resistance may have implications 
for the current IPTp policy and its outcome in Tanzania. 
Until alternative drugs for IPTp are available, routine 
monitoring of clinical outcome of IPTp and continuous 
monitoring of SP super-resistance markers is necessary.
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